US BioTec Inc banner
U

US BioTec Inc
OTC:USBC

Watchlist Manager
US BioTec Inc
OTC:USBC
Watchlist
Price: 0.4 USD 8.11% Market Closed
Market Cap: $155.3m

Relative Value

USBC doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of USBC.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

USBC Relative Value
Base Case
Not Available
U
Worst Case
Base Case
Best Case

Multiples Across Competitors

USBC Competitors Multiples
US BioTec Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
US BioTec Inc
OTC:USBC
155.3m USD 0 0 0 0
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
415.6B USD 6.8 98.9 16.2 22.5
US
Amgen Inc
NASDAQ:AMGN
204.5B USD 5.5 26.4 15.1 15.1
US
Gilead Sciences Inc
NASDAQ:GILD
184.3B USD 6.2 21.6 13.4 16.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD 10 30.5 23 24
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.6B USD 5.7 18.1 13.5 15.4
AU
CSL Ltd
ASX:CSL
69.1B AUD 3.2 35.1 11.6 14.5
NL
argenx SE
XBRU:ARGX
39.4B EUR 11.2 36 39.2 40
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
P/S Multiple
Revenue Growth P/S to Growth
US
U
US BioTec Inc
OTC:USBC
Average P/S: 3 369 303.3
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.8
9%
0.8
US
Amgen Inc
NASDAQ:AMGN
5.5
3%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
6.2
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10
11%
0.9
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
10%
0.6
AU
CSL Ltd
ASX:CSL
3.2
4%
0.8
NL
argenx SE
XBRU:ARGX
11.2
28%
0.4
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
US
U
US BioTec Inc
OTC:USBC
Average P/E: 38.1
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
98.9
96%
1
US
Amgen Inc
NASDAQ:AMGN
26.4
18%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
21.6
14%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.5
17%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.1
13%
1.4
AU
CSL Ltd
ASX:CSL
35.1
11%
3.2
NL
argenx SE
XBRU:ARGX
36
35%
1
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
U
US BioTec Inc
OTC:USBC
Average EV/EBITDA: 18.8
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.2
12%
1.3
US
Amgen Inc
NASDAQ:AMGN
15.1
10%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
13.4
9%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.5
18%
0.8
AU
CSL Ltd
ASX:CSL
11.6
7%
1.7
NL
argenx SE
XBRU:ARGX
39.2
49%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
U
US BioTec Inc
OTC:USBC
Average EV/EBIT: 21.2
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.5
24%
0.9
US
Amgen Inc
NASDAQ:AMGN
15.1
3%
5
US
Gilead Sciences Inc
NASDAQ:GILD
16.6
13%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.4
23%
0.7
AU
CSL Ltd
ASX:CSL
14.5
10%
1.5
NL
argenx SE
XBRU:ARGX
40
56%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett